Dr. Mona Rady | Education and Research | Best Researcher Award

Dr. Mona Rady | Education and Research | Best Researcher Award

German University in Cairo (GUC) and German International University (GIU) | Egypt

Dr. Mona Rady, PhD, is a Lecturer in Microbiology, Immunology, and Biotechnology at the German University in Cairo (GUC) and the German International University (GIU), with over 19 years of teaching and research experience. She earned her PhD in Microbiology and Immunology from GUC in 2014, following an MSc in Pharmacology and Toxicology (2009) and a BSc in Pharmaceutical Sciences from Ain Shams University (2002). She recently completed an MSc in Public Health at the University of South Wales, UK (2023). Her research interests focus on cancer immunology, natural killer (NK) cell epitranscriptomics, immune modulation, immunotherapy, microbiome–immune interactions, and RNA modifications such as m6A. She has supervised numerous PhD, MSc, and BSc theses, and her publication record reflects impactful contributions to NK cell biology and cancer immunology, with 7 documents, 179 citations, and an h-index of 7 on Google Scholar. Dr. Rady has received prestigious grants and fellowships including GERF-STDF, ASRT-BA, DAAD-GERSS, and Nature Publishing Group awards. She also serves as reviewer for journals such as Frontiers in Oncology and Immunology and Cell Biology. Through her multidisciplinary expertise, leadership in curriculum development, and international collaborations, Dr. Rady has established herself as a dedicated scientist advancing immunological research and education.

Profile: ORCID | Google Scholar

Featured Publications

 “Ginkgo biloba extract (EGb 761) mitigates methotrexate-induced testicular insult in rats: Targeting oxidative stress, energy deficit and spermatogenesis”

“The role of protein interaction domains in the human cancer network”

“Impact of N6-methyladenosine (m6A) modification on immunity”

“Pioglitazone attenuates lipopolysaccharide-induced oxidative stress, dopaminergic neuronal loss and neurobehavioral impairment by activating Nrf2/ARE/HO-1”

“Expression of RFC/SLC19A1 is associated with tumor type in bladder cancer patients”

“Altered expression of miR-181a and miR-146a does not change the expression of surface NCRs in human NK cells”

“Extracellular vesicles: from intracellular trafficking molecules to fully fortified delivery vehicles for cancer therapeutics”